Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

NCT04333706 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT04333706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04333706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
Lead sponsor
University of Southern California
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 26, 2020
Completion date
May 3, 2027
Enrollment
65 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast, cancer, disseminated tumor cell, metastatic, triple negative